Business Context and Reporting Period
Company: Elevai Labs Inc. (Note: Request metadata listed "PMGC Holdings Inc.", but the filing text identifies the registrant as Elevai Labs Inc., trading as ELAB on Nasdaq).
Reporting Period: Quarterly Report on Form 10-Q for the period ended September 30, 2024.
Business Overview: Elevai Labs operates three wholly-owned subsidiaries: Elevai Skincare Inc. (B2B/B2C skincare products), Elevai Biosciences, Inc. (biopharmaceutical development, specifically lead asset EL-22 for obesity/muscle preservation), and Elevai Research Inc. (Canadian R&D). The company is an emerging growth company and smaller reporting company.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $527,478 | $554,654 | $1,747,570 | $1,014,004 |
| Gross Profit | $393,901 | $366,145 | $1,278,807 | $672,882 |
| Gross Margin | 75% | 66% | 73% | 66% |
| Net Loss | $(1,501,257) | $(783,047) | $(4,310,998) | $(3,143,601) |
| Loss Per Share (Basic/Diluted) | $(0.068) | $(0.078) | $(0.226) | $(0.318) |
| Cash and Equivalents (End of Period) | $6,425,670 (as of Sept 30, 2024) | |||
| Working Capital | ||||
| Accumulated Deficit | $(11,334,888) (as of Sept 30, 2024) | |||
| Total Assets |
Cash Flow (YTD 9 Months):
- Operating Activities: $(3,486,435) used
- Investing Activities: $(171,480) used (primarily intangible assets)
- Financing Activities: $6,757,501 provided (equity issuance and notes)
Material Changes vs. Prior Period
- Revenue Growth: YTD revenue increased 72% ($733,566) compared to the prior year, driven by a 92% increase in Enfinity bottle sales and 27% increase in Empower tube sales. Q3 revenue declined slightly (5%) year-over-year due to the cessation of white-label distributor revenue in 2023.
- Expense Increases: YTD operating expenses rose 57% to $5.29 million. Significant increases were seen in Marketing and Promotion (+282%), Consulting Fees (+158%), and Office/Administration (+29%).
- Intangible Assets: The company acquired two significant licenses in 2024 (License #1 for stem cell technology and License #2 for engineered probiotics), resulting in $2.82 million in intangible assets on the balance sheet, compared to zero in the prior year.
- Equity Structure: Common shares outstanding increased from 17.3 million (Dec 2023) to 49.4 million (Sept 2024) due to public offerings and acquisitions. Subsequent to the period end, Series B warrants were exercised, significantly increasing share count.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy: Management plans to focus on revenue growth via existing infrastructure, clinical validation of products, R&D for new formulations, and advancing Elevai Biosciences assets to IND status. The company is also considering spin-offs of subsidiaries.
Going Concern: The filing includes a "Going Concern" warning. Despite raising capital, the company has an accumulated deficit of $11.3 million and incurred a net loss of $4.3 million YTD. Continued operations depend on further equity financing and achieving profitability.
Nasdaq Compliance: The company received a deficiency notice in May 2024 regarding minimum stockholders' equity. It submitted a plan and regained compliance by September 30, 2024, with equity exceeding $2.5 million.
Regulatory Issues: In March 2024, the company voluntarily stopped product sales in Canada following a communication from Health Canada regarding marketing practices. The Canadian distributor terminated its agreement in April 2024.
Unusual Items:
- Derivative Liabilities: A gain of $367,277 YTD was recorded due to the change in fair value of derivative liabilities (warrants), significantly reducing the reported net loss.
- Related Party Transactions: Significant consulting fees were paid to entities controlled by the Chairman and CEO. A $200,000 line of credit was drawn from a related party at 20% interest.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to secure additional funding given the $11.3M accumulated deficit and negative operating cash flow.
- Share Dilution: Review the impact of the subsequent exercise of Series B warrants (467M shares issued post-period) and the reset of warrant exercise prices to the floor price of $0.056.
- Canadian Operations: Assess the long-term impact of the Health Canada marketing issue and the loss of the Canadian distributor on future revenue streams.
- Intangible Asset Valuation: Scrutinize the $2.8M capitalized intangible assets (licenses) and the associated payment obligations ($950k remaining) to ensure fair value and future cash flow requirements.
- Related Party Conflicts: Review the terms of the $200k related-party line of credit (20% interest) and consulting agreements with management-controlled entities.